Page last updated: 2024-11-07

quinapyramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

quinapyramine: RN given refers to hydride; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122993
CHEMBL ID1398609
SCHEMBL ID291197
SCHEMBL ID14286196
MeSH IDM0047436

Synonyms (30)

Synonym
nsc-48223
NCI60_004145
n6-(2-imino-1,6-dimethyl-1,2-dihydro-4-pyrimidinyl)-1,2-dimethyl-15-quinoline-4,6-diamine
antrycide
quinolinium, 4-amino-6-[(2-amino-1,6-dimethyl-4(1h)-pyrimidinylidene)amino]-1,2-dimethyl-
23609-65-6
6-[(e)-(2-amino-1,6-dimethyl-pyrimidin-4-ylidene)amino]-1,2-dimethyl-quinolin-1-ium-4-amine
quinapyramine
NSC48223 ,
NCGC00013591
NCI48223
4-amino-6-((2-amino-1,6-dimethyl-4-pyrimidinyl)amino)-1-methylquinaldinium ion
quinolinium, 4-amino-6-((2-amino-1,6-dimethyl-4(1h)-pyrimidinylidene)amino)-1,2-dimethyl-, conjugate monoacid
NCISTRUC2_001482
NCISTRUC1_001223
NCGC00096704-01
CCG-36923
NCGC00013591-02
quinapyramine cation
20493-41-8
quinapyramine ion
b2nt1100wr ,
unii-b2nt1100wr
quinolinium, 4-amino-6-((1,2-dihydro-2-imino-1,6-dimethyl-4-pyrimidinyl)amino)-1,2-dimethyl-
quinapyramine [mi]
1082114-38-2
SCHEMBL291197
SCHEMBL14286196
CHEMBL1398609
6-[(2-amino-1,6-dimethylpyrimidin-4-ylidene)amino]-1,2-dimethylquinolin-1-ium-4-amine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"We synthesized quinapyramine sulfate loaded-sodium alginate nanoparticles (QS-NPs) to reduce undesirable toxic effects of QS against the parasite Trypanosoma evansi, a causative agent of trypanosomosis."( Cytotoxicity and genotoxicity of a trypanocidal drug quinapyramine sulfate loaded-sodium alginate nanoparticles in mammalian cells.
Bajaj, A; Chopra, M; Dilbaghi, N; Kumar, B; Kumar, R; Kumar, S; Manuja, A; Riyesh, T; Singh, S; Yadav, SC, 2016
)
1.04

Bioavailability

ExcerptReferenceRelevance
" It therefore appears that drug bioavailability is altered or drug biotransformation occurs during the in vivo test."( In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to diminazene, suramin, MelCy, quinapyramine and isometamidium.
Baltz, T; Giroud, C; Zhang, ZQ, 1991
)
0.5

Dosage Studied

ExcerptRelevanceReference
" The activity of each drug was expressed as: 1) in vitro: the minimal effective concentration which killed trypanosome population by 100% within 24 h of drug exposure (MEC100); the maximum tolerated concentration in which trypanosomes could propagate at the same rate as the controls during 48 h of drug exposure (MTC100); 2) in vivo: the curative dosage in 100% of infected mice (CD100); the highest ineffective dosage: 100% of infected mice remain infected (ID100)."( In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to diminazene, suramin, MelCy, quinapyramine and isometamidium.
Baltz, T; Giroud, C; Zhang, ZQ, 1991
)
0.5
" In vivo experiments in mice with selected isolates showed that the isolate most resistant to suramin was not cured at a dosage of 10 mg/kg, while the isolate that was most resistant to antrycide showed only 50% cure rate at a dose rate of 5 mg/kg."( Resistance to drug by different isolates Trypanosoma evansi in China.
Liao, D; Lin, J; Shen, J; Zhou, J; Zhou, Y, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency7.94330.012610.691788.5700AID887
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.79430.28189.721235.4813AID2326
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (80)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (62.50)18.7374
1990's13 (16.25)18.2507
2000's5 (6.25)29.6817
2010's10 (12.50)24.3611
2020's2 (2.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.26 (24.57)
Research Supply Index4.41 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index50.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.70%)6.00%
Case Studies1 (1.23%)4.05%
Observational0 (0.00%)0.25%
Other77 (95.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]